180 related articles for article (PubMed ID: 28800598)
1. An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection.
Blanco N; Foxman B; Malani AN; Zhang M; Walk S; Rickard AH; Eisenberg MC
PLoS One; 2017; 12(8):e0182815. PubMed ID: 28800598
[TBL] [Abstract][Full Text] [Related]
2. High sporulation and overexpression of virulence factors in biofilms and reduced susceptibility to vancomycin and linezolid in recurrent Clostridium [Clostridioides] difficile infection isolates.
Tijerina-Rodríguez L; Villarreal-Treviño L; Baines SD; Morfín-Otero R; Camacho-Ortíz A; Flores-Treviño S; Maldonado-Garza H; Rodríguez-Noriega E; Garza-González E
PLoS One; 2019; 14(7):e0220671. PubMed ID: 31365590
[TBL] [Abstract][Full Text] [Related]
3. Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model.
Freeman J; Marquis M; Crowther GS; Todhunter SL; Fawley WN; Chilton CH; Moeck G; Lehoux D; Wilcox MH
J Antimicrob Chemother; 2012 Dec; 67(12):2919-26. PubMed ID: 22899803
[TBL] [Abstract][Full Text] [Related]
4. Clinical, epidemiological and microbiological characteristics of relapse and re-infection in Clostridium difficile infection.
Gómez S; Chaves F; Orellana MA
Anaerobe; 2017 Dec; 48():147-151. PubMed ID: 28830842
[TBL] [Abstract][Full Text] [Related]
5. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses.
Cornely OA; Vehreschild MJGT; Adomakoh N; Georgopali A; Karas A; Kazeem G; Guery B
Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1187-1194. PubMed ID: 30911926
[TBL] [Abstract][Full Text] [Related]
6. Germination efficiency of clinical Clostridium difficile spores and correlation with ribotype, disease severity and therapy failure.
Moore P; Kyne L; Martin A; Solomon K
J Med Microbiol; 2013 Sep; 62(Pt 9):1405-1413. PubMed ID: 23518657
[TBL] [Abstract][Full Text] [Related]
7. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model.
Baines SD; O'Connor R; Saxton K; Freeman J; Wilcox MH
J Antimicrob Chemother; 2008 Nov; 62(5):1078-85. PubMed ID: 18772161
[TBL] [Abstract][Full Text] [Related]
8. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model.
Baines SD; O'Connor R; Saxton K; Freeman J; Wilcox MH
J Antimicrob Chemother; 2009 Mar; 63(3):520-5. PubMed ID: 19112083
[TBL] [Abstract][Full Text] [Related]
9. Molecular characteristics of Clostridium difficile strains from patients with a first recurrence more than 8 weeks after the primary infection.
Chen Y; Rashid MU; Huang H; Fang H; Nord CE; Wang M; Weintraub A
J Microbiol Immunol Infect; 2017 Aug; 50(4):532-536. PubMed ID: 26698688
[TBL] [Abstract][Full Text] [Related]
10. Outcome of relapsing Clostridium difficile infections do not correlate with virulence-, spore- and vegetative cell-associated phenotypes.
Plaza-Garrido Á; Miranda-Cárdenas C; Castro-Córdova P; Olguín-Araneda V; Cofré-Araneda G; Hernández-Rocha C; Carman R; Ibáñez P; Fawley WN; Wilcox MH; Gil F; Calderón IL; Fuentes JA; Guzmán-Durán AM; Alvarez-Lobos M; Paredes-Sabja D
Anaerobe; 2015 Dec; 36():30-8. PubMed ID: 26403333
[TBL] [Abstract][Full Text] [Related]
11. An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy.
Bouza E; Alcalá L; Marín M; Valerio M; Reigadas E; Muñoz P; González-Del Vecchio M; de Egea V
Eur J Clin Microbiol Infect Dis; 2017 Oct; 36(10):1777-1786. PubMed ID: 28501926
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis of early stages of Clostridium difficile infection: germination and colonization.
Sarker MR; Paredes-Sabja D
Future Microbiol; 2012 Aug; 7(8):933-43. PubMed ID: 22913353
[TBL] [Abstract][Full Text] [Related]
13. Two Clusters of Fluoroquinolone and Clindamycin-Resistant Clostridium difficile PCR Ribotype 001 Strain Recognized by Capillary Electrophoresis Ribotyping and Multilocus Variable Tandem Repeat Analysis.
Nyc O; Tejkalova R; Kriz Z; Ruzicka F; Kubicek L; Matejkova J; Kuijper E; Krutova M
Microb Drug Resist; 2017 Jul; 23(5):609-615. PubMed ID: 27860531
[TBL] [Abstract][Full Text] [Related]
14. Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.
Warn P; Thommes P; Sattar A; Corbett D; Flattery A; Zhang Z; Black T; Hernandez LD; Therien AG
Antimicrob Agents Chemother; 2016 Nov; 60(11):6471-6482. PubMed ID: 27527088
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model.
Chilton CH; Crowther GS; Todhunter SL; Ashwin H; Longshaw CM; Karas A; Wilcox MH
J Antimicrob Chemother; 2015 Sep; 70(9):2598-607. PubMed ID: 26078392
[TBL] [Abstract][Full Text] [Related]
16.
Zhu D; Sorg JA; Sun X
Front Cell Infect Microbiol; 2018; 8():29. PubMed ID: 29473021
[No Abstract] [Full Text] [Related]
17. Characterization of Chicken IgY Specific to
Pizarro-Guajardo M; Díaz-González F; Álvarez-Lobos M; Paredes-Sabja D
Front Cell Infect Microbiol; 2017; 7():365. PubMed ID: 28856119
[No Abstract] [Full Text] [Related]
18. SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.
Sattar A; Thommes P; Payne L; Warn P; Vickers RJ
J Antimicrob Chemother; 2015; 70(6):1757-62. PubMed ID: 25652749
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection.
Crowther GS; Baines SD; Todhunter SL; Freeman J; Chilton CH; Wilcox MH
J Antimicrob Chemother; 2013 Jan; 68(1):168-76. PubMed ID: 22966180
[TBL] [Abstract][Full Text] [Related]
20. Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics.
van Beurden YH; Nezami S; Mulder CJJ; Vandenbroucke-Grauls CMJE
Clin Microbiol Infect; 2018 Jan; 24(1):85.e1-85.e4. PubMed ID: 28782647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
